Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,987 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population.
Nakamura N, Kanemura N, Matsumoto T, Nakamura H, Ikoma Y, Shibata Y, Kitagawa J, Kasahara S, Yamada T, Sawada M, Kaneda Y, Fukuno K, Takada E, Goto H, Lee S, Fujita K, Morishita T, Hara T, Tsurumi H, Shimizu M. Nakamura N, et al. Among authors: yamada t. Sci Rep. 2023 Nov 4;13(1):19060. doi: 10.1038/s41598-023-46501-5. Sci Rep. 2023. PMID: 37925551 Free PMC article.
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.
Nakamura N, Goto N, Tsurumi H, Takemura M, Kanemura N, Kasahara S, Hara T, Yasuda I, Shimizu M, Sawada M, Yamada T, Seishima M, Takami T, Moriwaki H. Nakamura N, et al. Among authors: yamada t. Eur J Haematol. 2013 Oct;91(4):322-31. doi: 10.1111/ejh.12139. Epub 2013 Jul 7. Eur J Haematol. 2013. PMID: 23672298
CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y, Hara T, Kasahara S, Yamada T, Sawada M, Mabuchi R, Matsumoto T, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Kito Y, Goto N, Miyazaki T, Takami T, Takeuchi T, Shimizu M, Tsurumi H. Shibata Y, et al. Among authors: yamada t. Hematol Oncol. 2017 Jun;35(2):163-171. doi: 10.1002/hon.2262. Epub 2015 Oct 9. Hematol Oncol. 2017. PMID: 26449182
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T, Hara T, Shibata Y, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Goto N, Kito Y, Kasahara S, Yamada T, Sawada M, Miyazaki T, Takami T, Takeuchi T, Moriwaki H, Tsurumi H. Matsumoto T, et al. Among authors: yamada t. Hematol Oncol. 2017 Sep;35(3):288-295. doi: 10.1002/hon.2285. Epub 2016 Mar 21. Hematol Oncol. 2017. PMID: 26999778
R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Nannya Y, Katsumura N, Takahashi T, Kito Y, Takami T, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H. Hara T, et al. Among authors: yamada t. Hematol Oncol. 2018 Oct;36(4):638-644. doi: 10.1002/hon.2524. Epub 2018 Jun 8. Hematol Oncol. 2018. PMID: 29882279 Clinical Trial.
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H. Sawada M, et al. Among authors: yamada t. Eur J Haematol. 2002 Jun;68(6):354-61. doi: 10.1034/j.1600-0609.2002.01654.x. Eur J Haematol. 2002. PMID: 12225393 Free article. Clinical Trial.
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H. Goto H, et al. Among authors: yamada t. J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9. doi: 10.1007/s00432-004-0600-9. Epub 2004 Oct 21. J Cancer Res Clin Oncol. 2005. PMID: 15503137
Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M, Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Kojima Y, et al. Among authors: yamada t. Eur J Haematol. 2006 Jun;76(6):465-72. doi: 10.1111/j.1600-0609.2006.00631.x. Epub 2006 Feb 23. Eur J Haematol. 2006. PMID: 16494623 Free article.
11,987 results
You have reached the last available page of results. Please see the User Guide for more information.